HRP20000310A2 - New dibenzoazulene compounds as tumor necrosis factor inhibitors - Google Patents
New dibenzoazulene compounds as tumor necrosis factor inhibitors Download PDFInfo
- Publication number
- HRP20000310A2 HRP20000310A2 HR20000310A HRP20000310A HRP20000310A2 HR P20000310 A2 HRP20000310 A2 HR P20000310A2 HR 20000310 A HR20000310 A HR 20000310A HR P20000310 A HRP20000310 A HR P20000310A HR P20000310 A2 HRP20000310 A2 HR P20000310A2
- Authority
- HR
- Croatia
- Prior art keywords
- dibenzo
- azulen
- ylmethoxy
- ethyl
- dithia
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 62
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
- 238000006243 chemical reaction Methods 0.000 claims description 63
- -1 cyano, amino Chemical group 0.000 claims description 54
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 31
- 239000011541 reaction mixture Substances 0.000 claims description 28
- 238000004440 column chromatography Methods 0.000 claims description 25
- 238000010992 reflux Methods 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 22
- 238000000746 purification Methods 0.000 claims description 21
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000001953 recrystallisation Methods 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- JTXULCJEMDHNBH-UHFFFAOYSA-N C12=CC=C(Cl)C=C2SC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 Chemical compound C12=CC=C(Cl)C=C2SC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 JTXULCJEMDHNBH-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000005110 aryl thio group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 2
- RNHSJWDRJGCMOR-UHFFFAOYSA-N C12=CC(F)=CC=C2OC2=CC=CC=C2C2=C1SC(CCC(=O)O)=C2 Chemical compound C12=CC(F)=CC=C2OC2=CC=CC=C2C2=C1SC(CCC(=O)O)=C2 RNHSJWDRJGCMOR-UHFFFAOYSA-N 0.000 claims description 2
- QIZJVNKFGXAYPR-UHFFFAOYSA-N Cl.C12=CC=C(Br)C=C2SC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 Chemical compound Cl.C12=CC=C(Br)C=C2SC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 QIZJVNKFGXAYPR-UHFFFAOYSA-N 0.000 claims description 2
- RZGJWVFLDKZTTI-UHFFFAOYSA-L Cl[Cr](=O)(=O)OC1=CC=CC=N1 Chemical compound Cl[Cr](=O)(=O)OC1=CC=CC=N1 RZGJWVFLDKZTTI-UHFFFAOYSA-L 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 101150020251 NR13 gene Proteins 0.000 claims description 2
- RHHSGLPWDHEVIR-UHFFFAOYSA-L O[Cr](O[Cr](OC1=CC=CC=N1)(=O)=O)(=O)=O Chemical compound O[Cr](O[Cr](OC1=CC=CC=N1)(=O)=O)(=O)=O RHHSGLPWDHEVIR-UHFFFAOYSA-L 0.000 claims description 2
- 150000003973 alkyl amines Chemical class 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 150000007860 aryl ester derivatives Chemical class 0.000 claims description 2
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000004970 halomethyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 238000003408 phase transfer catalysis Methods 0.000 claims description 2
- 239000003444 phase transfer catalyst Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims 12
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000012454 non-polar solvent Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000020477 pH reduction Effects 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229910052703 rhodium Inorganic materials 0.000 claims 1
- 239000010948 rhodium Substances 0.000 claims 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 76
- 238000005160 1H NMR spectroscopy Methods 0.000 description 64
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 64
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 64
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000000243 solution Substances 0.000 description 42
- 102100040247 Tumor necrosis factor Human genes 0.000 description 35
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 29
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 24
- 108010002352 Interleukin-1 Proteins 0.000 description 24
- 102000000589 Interleukin-1 Human genes 0.000 description 24
- 239000002158 endotoxin Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 14
- LJQNMDZRCXJETK-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine;hydron;chloride Chemical compound Cl.CN(C)CCCCl LJQNMDZRCXJETK-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- VFLQQZCRHPIGJU-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine;hydron;chloride Chemical compound Cl.ClCCN1CCCCC1 VFLQQZCRHPIGJU-UHFFFAOYSA-N 0.000 description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000006433 tumor necrosis factor production Effects 0.000 description 7
- GXMSLNZIHPZWAI-UHFFFAOYSA-N 5-thiatetracyclo[12.4.0.02,6.08,13]octadeca-1(18),2,6,8,10,12,14,16-octaene Chemical class S1CC=C2C3=C(C4=C(C=C12)C=CC=C4)C=CC=C3 GXMSLNZIHPZWAI-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000000160 carbon, hydrogen and nitrogen elemental analysis Methods 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000018276 interleukin-1 production Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000004963 pathophysiological condition Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000651 prodrug Chemical group 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- KAANTNXREIRLCT-UHFFFAOYSA-N 1-(triphenyl-$l^{5}-phosphanylidene)propan-2-one Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)C)C1=CC=CC=C1 KAANTNXREIRLCT-UHFFFAOYSA-N 0.000 description 1
- WNSVNBQGIRRNLR-UHFFFAOYSA-N 1-[2-(13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),4,7,9,11,14,16-octaen-4-ylmethoxy)ethyl]piperidine hydrochloride Chemical compound Cl.C=1C(C2=CC=CC=C2OC2=CC=CC=C22)=C2SC=1COCCN1CCCCC1 WNSVNBQGIRRNLR-UHFFFAOYSA-N 0.000 description 1
- SQNXZINOQZHERU-UHFFFAOYSA-N 1-[2-(13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),4,7,9,11,14,16-octaen-4-ylmethoxy)ethyl]pyrrolidine hydrochloride Chemical compound Cl.C=1C(C2=CC=CC=C2OC2=CC=CC=C22)=C2SC=1COCCN1CCCC1 SQNXZINOQZHERU-UHFFFAOYSA-N 0.000 description 1
- POXOJRBFXVLJJG-UHFFFAOYSA-N 1-[2-[[16-(trifluoromethyl)-3,13-dithiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl]methoxy]ethyl]pyrrolidine hydrochloride Chemical compound Cl.C=1C=2C3=CC=CC=C3SC3=CC(C(F)(F)F)=CC=C3C=2SC=1COCCN1CCCC1 POXOJRBFXVLJJG-UHFFFAOYSA-N 0.000 description 1
- SSGLEOCDWJFZPE-UHFFFAOYSA-N 2-[(17-fluoro-3,13-dithiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)methoxy]-N,N-dimethylethanamine hydrochloride Chemical compound Cl.C12=CC(F)=CC=C2SC2=CC=CC=C2C2=C1SC(COCCN(C)C)=C2 SSGLEOCDWJFZPE-UHFFFAOYSA-N 0.000 description 1
- OCWGRWAYARCRTQ-UHFFFAOYSA-N 2-chloro-n,n-dimethylpropan-1-amine;hydron;chloride Chemical compound Cl.CC(Cl)CN(C)C OCWGRWAYARCRTQ-UHFFFAOYSA-N 0.000 description 1
- WZGUWRZWSVYUGA-UHFFFAOYSA-N 3-(17-fluoro-13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)prop-2-enoic acid Chemical compound C12=CC(F)=CC=C2OC2=CC=CC=C2C2=C1SC(C=CC(=O)O)=C2 WZGUWRZWSVYUGA-UHFFFAOYSA-N 0.000 description 1
- MJWIOSFQVSLWCV-UHFFFAOYSA-N 3-[(15,17-dimethyl-3,13-dithiatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),4,7,9,11,14,16-octaen-4-yl)methoxy]-N,N-dimethylpropan-1-amine hydrochloride Chemical compound Cl.C12=CC(C)=CC(C)=C2SC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 MJWIOSFQVSLWCV-UHFFFAOYSA-N 0.000 description 1
- NMBGCBJQNLIVPD-UHFFFAOYSA-N 3-[(15-chloro-13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)methoxy]-N,N-dimethylpropan-1-amine Chemical compound C12=CC=CC(Cl)=C2OC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 NMBGCBJQNLIVPD-UHFFFAOYSA-N 0.000 description 1
- PXCXNYYBFSAIKL-UHFFFAOYSA-N 3-[(15-chloro-17-fluoro-3,13-dithiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)methoxy]-N,N-dimethylpropan-1-amine hydrochloride Chemical compound Cl.C12=CC(F)=CC(Cl)=C2SC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 PXCXNYYBFSAIKL-UHFFFAOYSA-N 0.000 description 1
- HROMICXIICYESN-UHFFFAOYSA-N 4-(17-chloro-13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)but-3-en-2-one Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2C2=C1SC(C=CC(=O)C)=C2 HROMICXIICYESN-UHFFFAOYSA-N 0.000 description 1
- LSLDGAZGQWNMFR-UHFFFAOYSA-N 4-(17-fluoro-13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)but-3-en-2-one Chemical compound C12=CC(F)=CC=C2OC2=CC=CC=C2C2=C1SC(C=CC(=O)C)=C2 LSLDGAZGQWNMFR-UHFFFAOYSA-N 0.000 description 1
- MZDXSRNKEWMDCM-UHFFFAOYSA-N 4-[2-(13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),4,7,9,11,14,16-octaen-4-ylmethoxy)ethyl]morpholine hydrochloride Chemical compound Cl.C=1C(C2=CC=CC=C2OC2=CC=CC=C22)=C2SC=1COCCN1CCOCC1 MZDXSRNKEWMDCM-UHFFFAOYSA-N 0.000 description 1
- IMIOAEASDNIJFA-UHFFFAOYSA-N 4-[2-[(17-bromo-3,13-dithiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)methoxy]ethyl]morpholine Chemical compound S1C=2C3=CC(Br)=CC=C3SC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 IMIOAEASDNIJFA-UHFFFAOYSA-N 0.000 description 1
- ODQNCXWUCFPGSW-UHFFFAOYSA-N 4-[2-[(17-fluoro-13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)methoxy]ethyl]morpholine hydrochloride Chemical compound Cl.S1C=2C3=CC(F)=CC=C3OC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 ODQNCXWUCFPGSW-UHFFFAOYSA-N 0.000 description 1
- BRIQGBRVLIIVKY-UHFFFAOYSA-N 4-[2-[(17-fluoro-3,13-dithiatetracyclo[12.4.0.02,6.07,12]octadeca-1(14),2(6),4,7,9,11,15,17-octaen-4-yl)methoxy]ethyl]morpholine hydrochloride Chemical compound Cl.S1C=2C3=CC(F)=CC=C3SC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 BRIQGBRVLIIVKY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- LXOIYMFFJOSPIF-UHFFFAOYSA-N C12=CC(Cl)=CC=C2OC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2C2=C1SC(COCCCN(C)C)=C2 LXOIYMFFJOSPIF-UHFFFAOYSA-N 0.000 description 1
- IDFAGQUZTTZUDL-UHFFFAOYSA-N C=1C=2C3=CC=CC=C3OC=3C(Cl)=CC=CC=3C=2SC=1COCCN1CCOCC1 Chemical compound C=1C=2C3=CC=CC=C3OC=3C(Cl)=CC=CC=3C=2SC=1COCCN1CCOCC1 IDFAGQUZTTZUDL-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- BIIWZXUFHNODJC-UHFFFAOYSA-N Cl.C12=CC(Br)=CC=C2SC2=CC=CC=C2C2=C1SC(COCCN(C)C)=C2 Chemical compound Cl.C12=CC(Br)=CC=C2SC2=CC=CC=C2C2=C1SC(COCCN(C)C)=C2 BIIWZXUFHNODJC-UHFFFAOYSA-N 0.000 description 1
- PFQZUHVVDDOURF-UHFFFAOYSA-N Cl.C12=CC(Cl)=CC=C2SC2=CC=CC=C2C2=C1SC(COCCN(C)C)=C2 Chemical compound Cl.C12=CC(Cl)=CC=C2SC2=CC=CC=C2C2=C1SC(COCCN(C)C)=C2 PFQZUHVVDDOURF-UHFFFAOYSA-N 0.000 description 1
- GIUDILHULCTFCL-UHFFFAOYSA-N Cl.C12=CC=C(C(F)(F)F)C=C2SC2=CC=CC=C2C2=C1SC(COCCN(C)C)=C2 Chemical compound Cl.C12=CC=C(C(F)(F)F)C=C2SC2=CC=CC=C2C2=C1SC(COCCN(C)C)=C2 GIUDILHULCTFCL-UHFFFAOYSA-N 0.000 description 1
- HKPWVLDQXASOFI-UHFFFAOYSA-N Cl.C=1C(C2=CC=CC=C2SC2=CC=CC=C22)=C2SC=1COCCN1CCOCC1 Chemical compound Cl.C=1C(C2=CC=CC=C2SC2=CC=CC=C22)=C2SC=1COCCN1CCOCC1 HKPWVLDQXASOFI-UHFFFAOYSA-N 0.000 description 1
- AHUVELRDDLRYMA-UHFFFAOYSA-N Cl.S1C=2C3=CC(Cl)=CC=C3SC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 Chemical compound Cl.S1C=2C3=CC(Cl)=CC=C3SC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 AHUVELRDDLRYMA-UHFFFAOYSA-N 0.000 description 1
- TUDMUUAEEMBKKM-UHFFFAOYSA-N Cl.S1C=2C=3C=C(Cl)C(Cl)=CC=3SC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 Chemical compound Cl.S1C=2C=3C=C(Cl)C(Cl)=CC=3SC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 TUDMUUAEEMBKKM-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- WLCXQFOILVGYCV-UHFFFAOYSA-N N,N-dimethyl-2-(13-oxa-3-thiatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),4,7,9,11,14,16-octaen-4-ylmethoxy)ethanamine hydrochloride Chemical compound Cl.C12=CC=CC=C2OC2=CC=CC=C2C2=C1SC(COCCN(C)C)=C2 WLCXQFOILVGYCV-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- NMTFQBGBACMSPP-UHFFFAOYSA-N S1C=2C3=CC(Cl)=CC=C3OC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 Chemical compound S1C=2C3=CC(Cl)=CC=C3OC3=CC=CC=C3C=2C=C1COCCN1CCOCC1 NMTFQBGBACMSPP-UHFFFAOYSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- KKMXNGLNAMDYPV-UHFFFAOYSA-N [Cl-].C(C1=CC=CC=C1)[NH2+]C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound [Cl-].C(C1=CC=CC=C1)[NH2+]C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 KKMXNGLNAMDYPV-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- TWLCEYWYILDCDA-UHFFFAOYSA-N chromium(6+) oxygen(2-) pyridine Chemical compound [O-2].[O-2].[O-2].[Cr+6].C1=CC=NC=C1.C1=CC=NC=C1 TWLCEYWYILDCDA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical group 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 102220067365 rs143592561 Human genes 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (39)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20000310A HRP20000310A2 (en) | 2000-05-17 | 2000-05-17 | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
| EP01929882A EP1284977B1 (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| PT01929882T PT1284977E (pt) | 2000-05-17 | 2001-05-16 | Compostos de tienodibenzoazuleno como inibidores do factor de necrose tumoral |
| DK01929882T DK1284977T3 (da) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulenforbindelser som tumornekrosefaktorhæmmere |
| DE60139070T DE60139070D1 (de) | 2000-05-17 | 2001-05-16 | Thienodibenzazulenverbindungen als tumornekrosefaktorhemmer |
| MXPA02011269A MXPA02011269A (es) | 2000-05-17 | 2001-05-16 | Compuestos de tienodibenzoazuleno como inhibidores del factor necrosis tumoral. |
| GE5019A GEP20043304B (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene Compounds as Tumor Necrosis Factor Inhibitors |
| CNB018115896A CN1194976C (zh) | 2000-05-17 | 2001-05-16 | 作为肿瘤坏死因子抑制剂的噻吩并二苯并薁化合物 |
| YUP-841/02A RS50893B (sr) | 2000-05-17 | 2001-05-16 | Nova dibenzoazulen jedinjenja kao inhibitori faktora nekroze tumora |
| AT01929882T ATE434619T1 (de) | 2000-05-17 | 2001-05-16 | Thienodibenzazulenverbindungen als tumornekrosefaktorhemmer |
| JP2001584284A JP2003533528A (ja) | 2000-05-17 | 2001-05-16 | 腫瘍壊死因子抑制剤としてのチエノベンゾアズレン化合物 |
| CZ20024090A CZ301770B6 (cs) | 2000-05-17 | 2001-05-16 | Dibenzoazulenové deriváty jako inhibitory rakovinných nekróz a farmaceutický prostredek je obsahující |
| DZ013357A DZ3357A1 (fr) | 2000-05-17 | 2001-05-16 | Nouveaux médicaments composés de dibenzoazulène comme inhibiteurs de facteur onconécrosant |
| IL15280901A IL152809A0 (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| SI200130930T SI1284977T1 (sl) | 2000-05-17 | 2001-05-16 | Tienodibenzoazulenske spojine kot zaviralci tumorskega nekroznega faktorja |
| EA200201223A EA006069B1 (ru) | 2000-05-17 | 2001-05-16 | Тиенодибензоазуленовые соединения в качестве ингибиторов фактора некроза опухоли |
| KR1020027015567A KR100823064B1 (ko) | 2000-05-17 | 2001-05-16 | 종양 괴사 인자 억제제로서의 티에노디벤조아줄렌 화합물 |
| AU5656001A AU5656001A (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| HU0302295A HUP0302295A3 (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene derivatives, process for their preparation and use thereof |
| CA2409090A CA2409090C (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| NZ522553A NZ522553A (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| AU2001256560A AU2001256560B2 (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| PL365054A PL204849B1 (pl) | 2000-05-17 | 2001-05-16 | Pochodne dibenzoazulenu, sposób ich wytwarzania oraz zastosowanie |
| EEP200200636A EE200200636A (et) | 2000-05-17 | 2001-05-16 | Dibensoasuleeni derivaadid, nende valmistamismeetodid ja kasutamine |
| PCT/HR2001/000027 WO2001087890A1 (en) | 2000-05-17 | 2001-05-16 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| SK1770-2002A SK17702002A3 (sk) | 2000-05-17 | 2001-05-16 | Tienodibenzoazulénové zlúčeniny ako inhibítory rakovinových nekróz |
| BR0111202-3A BR0111202A (pt) | 2000-05-17 | 2001-05-16 | Compostos de tienodibenzoazuleno como inibidores do fator de necrose tumoral |
| ES01929882T ES2328335T3 (es) | 2000-05-17 | 2001-05-16 | Compuestos de tienodibenzoazuleno como inhibidores del factor de necrosis tumoral. |
| ARP010102339A AR030562A1 (es) | 2000-05-17 | 2001-05-17 | Derivados de dibenzoazuleno, su uso y procedimientos para prepararlos. |
| MA26901A MA27125A1 (fr) | 2000-05-17 | 2002-11-11 | Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose |
| ZA200209180A ZA200209180B (en) | 2000-05-17 | 2002-11-12 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors. |
| IS6621A IS6621A (is) | 2000-05-17 | 2002-11-14 | Þíenódíbensóasúlen efnasambönd sem hindrar fyrir æxlisdrepþátt |
| NO20025510A NO20025510L (no) | 2000-05-17 | 2002-11-15 | Dibenzoazulen-derivater samt anvendelse derav |
| US10/298,217 US6897211B2 (en) | 2000-05-17 | 2002-11-18 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| CR6860A CR6860A (es) | 2000-05-17 | 2002-12-17 | Nuevos compuestos de dibenzoazuleno inhibidores del factor a de necrosis tumoral |
| BG107399A BG65967B1 (bg) | 2000-05-17 | 2002-12-17 | Тиенодибензоазуленови съединения като инхибитори на туморен некрозен фактор |
| HK03109004A HK1056719A1 (en) | 2000-05-17 | 2003-12-11 | thienodibenzoazulene compounds as tumor necrosis factor inhibitors. |
| US11/090,743 US20050171091A1 (en) | 2000-05-17 | 2005-03-25 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| CY20091100888T CY1109328T1 (el) | 2000-05-17 | 2009-08-20 | Ενωσεις θειενοδιβενζοαζουλενιου ως αναστολεις παραγοντα νεκρωσης ογκου |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20000310A HRP20000310A2 (en) | 2000-05-17 | 2000-05-17 | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20000310A2 true HRP20000310A2 (en) | 2002-02-28 |
Family
ID=10947110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000310A HRP20000310A2 (en) | 2000-05-17 | 2000-05-17 | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US6897211B2 (es) |
| EP (1) | EP1284977B1 (es) |
| JP (1) | JP2003533528A (es) |
| KR (1) | KR100823064B1 (es) |
| CN (1) | CN1194976C (es) |
| AR (1) | AR030562A1 (es) |
| AT (1) | ATE434619T1 (es) |
| AU (2) | AU2001256560B2 (es) |
| BG (1) | BG65967B1 (es) |
| BR (1) | BR0111202A (es) |
| CA (1) | CA2409090C (es) |
| CR (1) | CR6860A (es) |
| CY (1) | CY1109328T1 (es) |
| CZ (1) | CZ301770B6 (es) |
| DE (1) | DE60139070D1 (es) |
| DK (1) | DK1284977T3 (es) |
| DZ (1) | DZ3357A1 (es) |
| EA (1) | EA006069B1 (es) |
| EE (1) | EE200200636A (es) |
| ES (1) | ES2328335T3 (es) |
| GE (1) | GEP20043304B (es) |
| HK (1) | HK1056719A1 (es) |
| HR (1) | HRP20000310A2 (es) |
| HU (1) | HUP0302295A3 (es) |
| IL (1) | IL152809A0 (es) |
| IS (1) | IS6621A (es) |
| MA (1) | MA27125A1 (es) |
| MX (1) | MXPA02011269A (es) |
| NO (1) | NO20025510L (es) |
| NZ (1) | NZ522553A (es) |
| PL (1) | PL204849B1 (es) |
| PT (1) | PT1284977E (es) |
| RS (1) | RS50893B (es) |
| SI (1) | SI1284977T1 (es) |
| SK (1) | SK17702002A3 (es) |
| WO (1) | WO2001087890A1 (es) |
| ZA (1) | ZA200209180B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262309B2 (en) | 2002-04-10 | 2007-08-28 | Glaxosmith Kline Istrazivocki Centar Zagreb, D.O.O. | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020304B1 (en) * | 2002-04-10 | 2008-04-30 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof |
| HRP20020305A8 (en) | 2002-04-10 | 2009-03-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| HRP20020440B1 (en) * | 2002-05-21 | 2008-02-29 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| HRP20020441A2 (en) * | 2002-05-21 | 2003-12-31 | Pliva D D | 1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof |
| HRP20020451A2 (en) | 2002-05-23 | 2003-12-31 | Pliva D D | 1-tia-3-aza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof |
| HRP20020452A2 (en) * | 2002-05-23 | 2004-02-29 | Pliva D D | 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof |
| HRP20020453A2 (en) | 2002-05-23 | 2003-12-31 | Pliva D D | 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof |
| HRP20030160A2 (en) * | 2003-03-06 | 2005-04-30 | Pliva-Istra�iva�ki institut d.o.o. | 1-thiadibenzoazulene derivatives and biological action thereof |
| HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
| WO2005047274A1 (en) * | 2003-11-12 | 2005-05-26 | Dr. Reddy's Laboratories, Inc. | Preparation of escitalopram |
| HRP20030954A2 (en) * | 2003-11-21 | 2005-08-31 | Pliva D.D. | USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| HRP20030955A2 (en) * | 2003-11-21 | 2005-08-31 | Pliva-Istra�iva�ki institut d.o.o. | USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| HRP20040104A2 (en) * | 2004-01-30 | 2005-10-31 | Pliva-Istra�iva�ki institut d.o.o. | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| US20090048221A1 (en) | 2004-10-27 | 2009-02-19 | Mladen Mercep | Conjugates with Anti-Inflammatory Activity |
| WO2006061392A2 (en) * | 2004-12-07 | 2006-06-15 | Janssen Pharmaceutica N.V. | Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives |
| JP2008532927A (ja) * | 2005-01-13 | 2008-08-21 | グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ | 抗炎症マクロライド接合体 |
| JP2009529057A (ja) | 2006-03-08 | 2009-08-13 | コートリア・コーポレーシヨン | Ｃｏｘ−関連胃損傷を予防するための非−選択的ｃｏｘ阻害剤との組み合わせ療法 |
| US8389482B2 (en) | 2007-01-30 | 2013-03-05 | New York University | Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species |
| WO2008096755A1 (ja) * | 2007-02-07 | 2008-08-14 | Nippon Suisan Kaisha, Ltd. | バニロイド受容体（ｖｒ１）阻害剤及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711489A (en) * | 1971-03-31 | 1973-01-16 | Pfizer | Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles |
| JPS53116385A (en) * | 1977-03-19 | 1978-10-11 | Hokuriku Pharmaceutical | Pyrazin derivative and method for its production |
| US4198421A (en) * | 1978-11-30 | 1980-04-15 | E. I. Du Pont De Nemours And Company | Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles |
| TR199801164T2 (xx) * | 1996-04-12 | 1998-10-21 | Janssen Pharmaceutica N.V. | S�bstit�e edilmi� tetrasiklik tetrahidrofuran t�revleri. |
| GB9713368D0 (en) * | 1997-06-25 | 1997-08-27 | Weston Medical Ltd | Flame control |
| EP0887339A1 (de) * | 1997-06-27 | 1998-12-30 | Roche Diagnostics GmbH | Neue Azulenderivate und diese enthaltende Arzneimittel |
-
2000
- 2000-05-17 HR HR20000310A patent/HRP20000310A2/hr not_active Application Discontinuation
-
2001
- 2001-05-16 JP JP2001584284A patent/JP2003533528A/ja active Pending
- 2001-05-16 SK SK1770-2002A patent/SK17702002A3/sk unknown
- 2001-05-16 DZ DZ013357A patent/DZ3357A1/fr active
- 2001-05-16 DE DE60139070T patent/DE60139070D1/de not_active Expired - Lifetime
- 2001-05-16 PT PT01929882T patent/PT1284977E/pt unknown
- 2001-05-16 CZ CZ20024090A patent/CZ301770B6/cs not_active IP Right Cessation
- 2001-05-16 RS YUP-841/02A patent/RS50893B/sr unknown
- 2001-05-16 NZ NZ522553A patent/NZ522553A/en unknown
- 2001-05-16 CA CA2409090A patent/CA2409090C/en not_active Expired - Fee Related
- 2001-05-16 MX MXPA02011269A patent/MXPA02011269A/es active IP Right Grant
- 2001-05-16 IL IL15280901A patent/IL152809A0/xx unknown
- 2001-05-16 DK DK01929882T patent/DK1284977T3/da active
- 2001-05-16 KR KR1020027015567A patent/KR100823064B1/ko not_active IP Right Cessation
- 2001-05-16 BR BR0111202-3A patent/BR0111202A/pt not_active Application Discontinuation
- 2001-05-16 GE GE5019A patent/GEP20043304B/en unknown
- 2001-05-16 EA EA200201223A patent/EA006069B1/ru not_active IP Right Cessation
- 2001-05-16 EE EEP200200636A patent/EE200200636A/xx unknown
- 2001-05-16 WO PCT/HR2001/000027 patent/WO2001087890A1/en active IP Right Grant
- 2001-05-16 CN CNB018115896A patent/CN1194976C/zh not_active Expired - Fee Related
- 2001-05-16 HU HU0302295A patent/HUP0302295A3/hu unknown
- 2001-05-16 ES ES01929882T patent/ES2328335T3/es not_active Expired - Lifetime
- 2001-05-16 EP EP01929882A patent/EP1284977B1/en not_active Expired - Lifetime
- 2001-05-16 AU AU2001256560A patent/AU2001256560B2/en not_active Ceased
- 2001-05-16 AT AT01929882T patent/ATE434619T1/de not_active IP Right Cessation
- 2001-05-16 SI SI200130930T patent/SI1284977T1/sl unknown
- 2001-05-16 PL PL365054A patent/PL204849B1/pl not_active IP Right Cessation
- 2001-05-16 AU AU5656001A patent/AU5656001A/xx active Pending
- 2001-05-17 AR ARP010102339A patent/AR030562A1/es active IP Right Grant
-
2002
- 2002-11-11 MA MA26901A patent/MA27125A1/fr unknown
- 2002-11-12 ZA ZA200209180A patent/ZA200209180B/en unknown
- 2002-11-14 IS IS6621A patent/IS6621A/is unknown
- 2002-11-15 NO NO20025510A patent/NO20025510L/no not_active Application Discontinuation
- 2002-11-18 US US10/298,217 patent/US6897211B2/en not_active Expired - Fee Related
- 2002-12-17 CR CR6860A patent/CR6860A/es not_active Application Discontinuation
- 2002-12-17 BG BG107399A patent/BG65967B1/bg unknown
-
2003
- 2003-12-11 HK HK03109004A patent/HK1056719A1/xx not_active IP Right Cessation
-
2005
- 2005-03-25 US US11/090,743 patent/US20050171091A1/en not_active Abandoned
-
2009
- 2009-08-20 CY CY20091100888T patent/CY1109328T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262309B2 (en) | 2002-04-10 | 2007-08-28 | Glaxosmith Kline Istrazivocki Centar Zagreb, D.O.O. | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20000310A2 (en) | New dibenzoazulene compounds as tumor necrosis factor inhibitors | |
| AU2001256560A1 (en) | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | |
| DE60302344T2 (de) | 1- oder 3-thia-benzonaphthoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung | |
| CN100354277C (zh) | 作为肿瘤坏死因子产生抑制剂的1,3－二氮杂－二苯并薁类和制备该抑制剂的中间体 | |
| DE60304048T2 (de) | 2-thia-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung | |
| US20060069149A1 (en) | Thiadibenzoazulene derivatives for the treatment of inflammatory diseases | |
| HRP20020441A2 (en) | 1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof | |
| DE60304047T2 (de) | 1-oxa-3-aza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung | |
| HRP20020451A2 (en) | 1-tia-3-aza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof | |
| HRP20020452A2 (en) | 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof | |
| KR20050016336A (ko) | 종양괴사인자 생성 억제제로서의 2-티아-디벤조아줄렌 및그의 제조를 위한 중간체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O., |
|
| PPPP | Transfer of rights |
Owner name: PLIVA-ISTRAZIVACKI INSTITUT D.O.O., HR |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20100512 Year of fee payment: 11 |
|
| ODBI | Application refused |